藥明生物(02269.HK)料上半年收入增長放緩 維持全年指引
藥明生物(02269.HK)昨日股價急挫17%收38.75元。公司今早公布,已於昨日(20日)召開投資者開放日。公司重申業務營運仍然正常,且業務營運和財務狀況概無發生重大不利變化。特別是在今年25個新項目中,很重要部分為III期臨床開發和商業化生產項目,而每個III期臨床開發和商業化生產項目在項目簽署後的第一年收入可能相當於臨床前開發項目的5至10倍左右。該些項目驗證客戶對公司商業化生產(CMO)能力和規模的信任,並預計將提升公司的近期收入。
公司預期,由於去年上半年基數較高,加上經過三年的高鐵速度式發展需暫停維護,今年上半年的收入增長將放緩。儘管挑戰重重,但仍維持全年指引。
公司指出,「贏得分子」戰略持續發力,截至今年5月31日,共有8個外部項目進入管線,包括4個第III期項目及2項CMO項目(重磅藥物)。上半年跟隨藥物分子的增長速度放緩,但贏得藥物分子加速第三期及重磅商業化藥物項目的增長。
此外,公司透露愛爾蘭基地於2025年幾乎全部預定,30%的項目基於全球雙廠生產自中國轉移(即跟隨藥物分子策略),而70%基於贏得分子策略(都是重磅生物藥)。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.